Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...
FierceBiotech2h
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...
Modifi Biosciences Acquired by Merck
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.
FierceBiotech2d
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Business Wire3d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG
Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...
Merck RSV therapy cuts respiratory infections by 60% in infants
Merck’s (NYSE:MRK) monoclonal antibody clesrovimab, designed as a prophylactic against respiratory syncytial virus (RSV), has ...
GlobalData on MSN12d
Merck unveils $318m biosafety testing facility in Maryland, US
Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...
Pharmabiz8d
Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and in combo with Welireg in RCC
Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...
Scoop7d
Merck Welcomes Funded Access To Cancer Treatment Erbitux® (Cetuximab)
From 1 November, a targeted cancer treatment will join the country’s Pharmaceutical Scheme for eligible New Zealanders diagnosed with a specific type of advanced bowel cancer. Globally recognised as a ...